Darunavir en la coinfección por VIH/VHB y/o VHC
Tài liệu tham khảo
Lima, 2007, Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy, AIDS, 21, 685, 10.1097/QAD.0b013e32802ef30c
Department of Human Health Service Panel on Antiretroviral Guidelines for Adults and Adolescents. Guideline for the use of antiretroviral agents in HIV-1-infected adults and adolescents: January 29, 2008. Disponible en: http://AIDSinfo.nih.gov
Panel de expertos de GESIDA y Plan Nacional sobre. el Sida Recomendaciones de GESIDA/PNS respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana (actualizado, Ene 2008). Disponible en: http://www.gesida.seimc.org
Clotet, 2007, Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials, Lancet, 369, 1169, 10.1016/S0140-6736(07)60497-8
Katlamaa, 2007, Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1, AIDS, 21, 395, 10.1097/QAD.0b013e328013d9d7
Ortiz, 2008, Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48, AIDS, 22, 1389, 10.1097/QAD.0b013e32830285fb
Konopnicki, 2005, Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort, AIDS, 19, 593, 10.1097/01.aids.0000163936.99401.fe
Mocroft, 2003, Decline in the AIDS and death rates in the EuroSIDA study: an observational study, Lancet, 362, 22, 10.1016/S0140-6736(03)13802-0
Mocroft, 2002, Changes in the cause of death among HIV positive subjects across Europe: Results from the EuroSIDA study, AIDS, 16, 1663, 10.1097/00002030-200208160-00012
Lewden, 2005, Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS, Int J Epidemiol, 34, 121, 10.1093/ije/dyh307
Rosenthal, 2007, Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study), J Viral Hepat, 14, 183, 10.1111/j.1365-2893.2006.00791.x
2006, Liver-related deaths in persons infected with the human immunodeficiency virus, The D:A:D Study, Arch Intern Med, 166, 1632, 10.1001/archinte.166.15.1632
Martínez, 2007, Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area, HIV Med, 8, 251, 10.1111/j.1468-1293.2007.00468.x
Benhamou, 1999, Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients, Hepatology, 30, 1054, 10.1002/hep.510300409
Graham, 2001, Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analisis, Clin Infect Dis, 3, 562, 10.1086/321909
Pineda, 2005, HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis, Hepatology, 41, 779, 10.1002/hep.20626
Merchante, 2006, Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease, AIDS, 20, 49, 10.1097/01.aids.0000198087.47454.e1
Puoti, 2004, Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome, AIDS, 18, 2285, 10.1097/00002030-200411190-00009
De Maat, 2002, Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals, Br J Clin Pharmacol, 54, 378, 10.1046/j.1365-2125.2002.01657.x
Sulkowski, 2004, Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors, Clin Infect Dis, 38, S90, 10.1086/381444
Regazzi, 2005, Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected patients, Antimicrob Agents Chemother, 49, 643, 10.1128/AAC.49.2.643-649.2005
Bonacini, 2004, Liver injury during highly active antiretroviral therapy: The effects of hepatitis C coinfection, Clin Infect Dis, 38, S104, 10.1086/381453
Rivero, 2007, Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors, J Antimicrob Chemother, 59, 342, 10.1093/jac/dkl524
Sulkowski, 2000, Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection, JAMA, 283, 74, 10.1001/jama.283.1.74
Sulkowski, 2004, Hepatotoxicity associated with protease inhibitor-based regimens with or without concurrent ritonavir, AIDS, 18, 2277, 10.1097/00002030-200411190-00008
Aceti, 2002, Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection, J Acquir Immune Defic Syndr, 29, 41, 10.1097/00042560-200201010-00005
Sulkowski, 2002, Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections, Hepatology, 35, 182, 10.1053/jhep.2002.30319
Spengler, 2002, Antiretroviral therapy- a challenge for the hepatologist?, J Hepatol, 36, 283, 10.1016/S0168-8278(01)00311-7
Aranzabal, 2005, Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection, Clin Infect Dis, 40, 588, 10.1086/427216
Carrat, 2004, Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial, JAMA, 292, 2839, 10.1001/jama.292.23.2839
Laguno, 2004, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients, AIDS, 18, F27, 10.1097/00002030-200409030-00003
Cargnel, 2005, Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART, Antivir Ther, 10, 309, 10.1177/135965350501000215
Hadziyannis, 2004, Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose, Ann Intern Med, 140, 346, 10.7326/0003-4819-140-5-200403020-00010
Pineda, 2007, Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy, Hepatology, 46, 622, 10.1002/hep.21757
Pozniak, 2007, Efficacy od darunavir in treatment-experienced HIV-1-infected patients at 96 weeks in the Power 1 and 2 trials
Arastéh, 2007, Efficacy analysis of darunavir in treatment-experienced POWER 3 patients at week 96
Yeni, 2007, Safety and tolerability of darunavir/ritonavir in treatment-experienced HIV-1-infected patients at 96 weeks in the Power 1,2 and 3 trials
Banhegyi, 2007, Tolerability of Darunavir/r versus Lopinavir/r in Lopinavir naïve, treatment-experienced, hepatitis B or C co-infected patients in TITAN
Ficha técnica de darunavir. EMEA, enero 2008.
Klein R, Struble K (FDA). Updates to Prezista (darunavir) tablets labeling. Community announcement. March 11, 2008.
FDA ALERT-FDA is highlighting the addition of information about hepatotoxicity to the WARNINGS section of the Prezista prescribing information. March 21, 2008.
Tennenberg A (Tibotec). Dear Healthcare Professional [setter]. March 11, 2008.
Rachlis, 2007, Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment experienced, hepatitis B or co-infected patients in POWER 1 and 3, HIV Clin Trials, 8, 213, 10.1310/hct0804-213
Ortiz R, Fourie J, Andrade-Villanueva J, Dincq S, Vanden Abeele C, Tomaka F, et al. Tolerability of once-daily darunavir/r versus lopinavir/r in treatmentnäive patients coinfected with hepatitis B and/or C in the ARTEMIS trial. Hep DART: frontiers in drug development for ARV. Hawai 2007. Póster 94.